Neurocrine Biosciences, Inc.
MX ˙ BMV ˙ US64125C1099
SecurityMX:NBIX / Neurocrine Biosciences, Inc.
InstitutionGrandfield & Dodd, Llc
Latest Disclosed Ownership16,462 shares
Latest Disclosed Value $ 2,168,704
Grandfield & Dodd, Llc reports 1.00% decrease in ownership of NBIX / Neurocrine Biosciences, Inc.

On May 7, 2026 - Grandfield & Dodd, Llc filed a 13F-HR form disclosing ownership of 16,462 shares of Neurocrine Biosciences, Inc. (MX:NBIX) valued at $2,168,704 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 10, 2026 disclosing 16,629 shares of Neurocrine Biosciences, Inc.. This represents a change in shares of -1.00% during the quarter.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-07 2026-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 16,462 -167 -1.00 2,169 -8.06 0.1224
2026-02-10 2025-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 16,629 3 0.02 2,358 1.07 0.1336
2025-10-30 2025-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 16,626 194 1.18 2,334 12.98 0.1324
2025-08-08 2025-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 16,432 -138 -0.83 2,065 12.72 0.1209
2025-05-02 2025-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 16,570 459 2.85 1,833 -16.69 0.1136
2025-02-06 2024-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 16,111 290 1.83 2,199 20.69 0.1356
2024-11-08 2024-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 15,821 280 1.80 1,823 -14.82 0.1080
2024-08-09 2024-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 15,541 -53 -0.34 2,140 -0.51 0.1355
2024-05-06 2024-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 15,594 203 1.32 2,151 6.07 0.1357
2024-01-31 2023-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 15,391 196 1.29 2,028 18.61 0.1401
2023-10-26 2023-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 15,195 -60 -0.39 1,709 18.85 0.1256
2023-08-08 2023-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 15,255 77 0.51 1,439 -6.38 0.1006
2023-04-28 2023-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 15,178 274 1.84 1,536 -13.71 0.1074
2023-01-20 2022-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 14,904 625 4.38 1,780 17.11 0.1302
2022-11-04 2022-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 14,279 352 2.53 1,520 11.76 0.1241
2022-08-01 2022-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 13,927 130 0.94 1,360 5.43 0.1071
2022-04-19 2022-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 13,797 566 4.28 1,290 14.16 0.0875
2022-02-08 2021-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 13,231 1,324 11.12 1,130 -0.88 0.0727
2021-10-28 2021-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 11,907 164 1.40 1,140 0.00 0.0796
2021-07-28 2021-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 11,743 190 1.64 1,140 1.79 0.0789
2021-04-22 2021-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 11,553 174 1.53 1,120 2.75 0.0837
2021-01-29 2020-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 11,379 262 2.36 1,090 1.87 0.0855
2020-11-03 2020-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 11,117 81 0.73 1,070 -20.74 0.0964
2020-07-24 2020-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 11,036 600 5.75 1,350 49.50 0.1306
2020-05-14 2020-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 10,436 430 4.30 903 -16.08 0.1065
2020-02-07 2019-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 10,006 540 5.70 1,076 26.14 0.0980
2019-10-30 2019-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 9,466 855 9.93 853 17.33 0.0839
2019-07-29 2019-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 8,611 730 9.26 727 4.76 0.0719
2019-04-26 2019-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 7,881 61 0.78 694 24.37 0.0723
2019-02-12 2018-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 7,820 65 0.84 558 -41.45 0.0660
2018-11-02 2018-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 7,755 70 0.91 953 26.23 0.0982
2018-07-27 2018-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 7,685 40 0.52 755 19.09 0.0830
2018-05-04 2018-03-31 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 7,645 -270 -3.41 634 3.26 0.0707
2018-05-04 2018-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 7,645 -270 634
2018-02-05 2017-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 7,915 305 4.01 614 31.76 0.0655
2017-11-03 2017-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 7,610 1,480 24.14 466 65.25 0.0523
2017-07-27 2017-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 6,130 810 15.23 282 22.61 0.0333
2017-04-28 2017-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 5,320 5,320 230 0.0284
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.